These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 25420994)

  • 1. Asthma: pathogenesis and novel drugs for treatment.
    Olin JT; Wechsler ME
    BMJ; 2014 Nov; 349():g5517. PubMed ID: 25420994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe asthma: advances in current management and future therapy.
    Barnes PJ
    J Allergy Clin Immunol; 2012 Jan; 129(1):48-59. PubMed ID: 22196524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].
    Drugs Today (Barc); 2008 Jun; 44 Suppl 3():1-43. PubMed ID: 19093041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difficult asthma: assessment and management, Part 2.
    Fanta CH; Long AA
    Allergy Asthma Proc; 2012; 33(4):313-23. PubMed ID: 22856632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids.
    Domingo C; Moreno A; Mirapeix R
    Intern Med J; 2011 Jul; 41(7):525-36. PubMed ID: 21762333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic interventions to reduce the risk of asthma exacerbations.
    O'Byrne PM
    Proc Am Thorac Soc; 2004; 1(2):105-8. PubMed ID: 16113421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF; Phipatanakul W
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.
    Naedele-Risha R; Dorinsky P; Craig TJ
    J Am Osteopath Assoc; 2001 Sep; 101(9):526-33. PubMed ID: 11575039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
    Chung KF
    J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to set up a severe asthma service.
    McDonald VM; Vertigan AE; Gibson PG
    Respirology; 2011 Aug; 16(6):900-11. PubMed ID: 21692918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summaries for patients. Omalizumab therapy for patients with severe asthma.
    Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934
    [No Abstract]   [Full Text] [Related]  

  • 14. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
    Di Stefano F; Cinti B; Antonicelli L
    Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):56-9. PubMed ID: 24702879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies to reduce asthma exacerbations.
    O'Byrne PM
    J Allergy Clin Immunol; 2011 Aug; 128(2):257-63; quiz 264-5. PubMed ID: 21531015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Poorly controlled asthma: diagnosis and therapeutics in children and adolescents].
    Neffen H; Vidaurreta S; Balanzat A; De Gennaro MS; Giubergia V; Maspero JF; Saranz RJ; Teper AM
    Medicina (B Aires); 2012; 72(5):403-13. PubMed ID: 23089117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic targeted therapy in allergic asthma.
    Bice JB; Leechawengwongs E; Montanaro A
    Ann Allergy Asthma Immunol; 2014 Feb; 112(2):108-15. PubMed ID: 24468249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab in the treatment of asthma.
    Tan R; Corren J
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.